Renal Cell Carcinoma

Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.

Latest News

Zachary BessettenccRCC | April 27, 2025

CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.

Zachary BessetteLocalized Renal Cell Carcinoma | April 27, 2025

A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.

Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.

Brandon TwyfordRenal Cell Carcinoma | April 26, 2025

Histologic subtype did not significantly affect 5-year cancer-specific survival after robotic partial nephrectomy for RCC.

Emily MenendeznccRCC | April 26, 2025

Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.

James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025

Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.

Curated clinical content based on conditions, therapies, and technologies

Samuel Gold, MDUrothelial Carcinoma | April 28, 2025

Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.

John Gore, MD, MSUrothelial Carcinoma | April 28, 2025

Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.

Joseph Jacob, MD, MCRUrothelial Carcinoma | April 28, 2025

Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.

Gautam T. Jayram, MDUrothelial Carcinoma | April 28, 2025

Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC.

Zachary BessettemCSPC | April 27, 2025

A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.

Brandon TwyfordProstate Cancer | April 27, 2025

Most patients in EMBARK recovered testosterone after treatment break, regardless of therapy or age.